Clinical Trial

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated April 9, 2026 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is an investigator-initiated, prospective, open-label, single-arm, multicenter clinical trial aimed at exploring the antitumor activity of Lorlatinib in ALK-positive NSCLC patients with brain/ leptomeningeal metastases.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-02-21.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-04-03
Trial Details
NCT Number NCT06282874
Lead Sponsor Guangdong Association of Clinical Trials
Conditions Carcinoma, Non-Small-Cell Lung, Brain Metastases, Leptomeningeal Metastasis
Enrollment 41 participants
Start Date 2024-08-01
Primary Completion 2026-04-30 (estimated)
Study Completion 2027-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-09